Weight loss drugs can halve heart patients’ risk of early death, study finds

A large study presented at the European Society of Cardiology conference revealed that GLP-1 agonists, including semaglutide and tirzepatide, significantly reduce the risk of hospitalization or death for heart failure patients with obesity and type 2 diabetes. Analyzing data from over 90,000 patients, the study found tirzepatide cut this risk by 58% and semaglutide by 42%. This research, simultaneously published in JAMA, expands the therapeutic utility of these drugs beyond weight loss and diabetes, indicating a substantial new market opportunity and clinical application for millions of heart patients globally.

Analysis

A large-scale, real-world study of over 90,000 patients has provided compelling evidence for the cardiovascular benefits of GLP-1 agonists, significantly expanding their therapeutic application beyond weight loss and diabetes. The research, presented at the European Society of Cardiology conference and published in JAMA, found that tirzepatide from Eli Lilly (LLY) reduced the risk of hospitalization or all-cause mortality by 58% in heart failure patients with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes. In the same study, Novo-Nordisk's (NVO) semaglutide demonstrated a 42% risk reduction. These findings are particularly impactful as they address HFpEF, the most common form of heart failure with limited treatment options, potentially opening a substantial new market for both companies among the 60 million people with heart failure globally. Expert commentary suggests the mechanism may extend beyond simple weight loss, pointing to a direct cardioprotective effect, which reinforces the drugs' value proposition and supports a durable growth outlook for both LLY and NVO.

Key Decisions for Investors

• Investors should re-evaluate the total addressable market and long-term revenue forecasts for Eli Lilly and Novo-Nordisk, as this data strongly supports the expansion of their GLP-1 franchises into the large cardiology patient population.
• Eli Lilly's tirzepatide demonstrated a superior risk reduction of 58% versus 42% for Novo-Nordisk's semaglutide in this study, suggesting a potential competitive advantage for LLY in capturing market share within this specific heart failure cohort.
• The key catalysts to monitor will be the pace of adoption by cardiologists and the inclusion of these indications in official treatment guidelines, which will determine the speed and breadth of reimbursement coverage from payers.